Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

Författare

  • Yuan C. Ding
  • Lesley McGuffog
  • Sue Healey
  • Eitan Friedman
  • Yael Laitman
  • Shani Paluch-Shimon
  • Bella Kaufman
  • Annelie Liljegren
  • Annika Lindblom
  • Håkan Olsson
  • Ulf Kristoffersson
  • Marie Stenmark-Askmalm
  • Beatrice Melin
  • Susan M. Domchek
  • Katherine L. Nathanson
  • Timothy R. Rebbeck
  • Anna Jakubowska
  • Jan Lubinski
  • Katarzyna Jaworska
  • Katarzyna Durda
  • Jacek Gronwald
  • Tomasz Huzarski
  • Cezary Cybulski
  • Tomasz Byrski
  • Ana Osorio
  • Teresa Ramony Cajal
  • Alexandra V. Stavropoulou
  • Javier Benitez
  • Ute Hamann
  • Matti Rookus
  • Cora M. Aalfs
  • Judith L. de Lange
  • Hanne E. J. Meijers-Heijboer
  • Jan C. Oosterwijk
  • Christi J. van Asperen
  • Encarna B. Gomez Garcia
  • Nicoline Hoogerbrugge
  • Agnes Jager
  • Rob B. van der Luijt
  • Douglas F. Easton
  • Susan Peock
  • Debra Frost
  • Steve D. Ellis
  • Radka Platte
  • Elena Fineberg
  • D. Gareth Evans
  • Fiona Lalloo
  • Louise Izatt
  • Ros Eeles
  • Julian Adlard
  • Rosemarie Davidson
  • Diana Eccles
  • Trevor Cole
  • Jackie Cook
  • Carole Brewer
  • Marc Tischkowitz
  • Andrew K. Godwin
  • Harsh Pathak
  • Dominique Stoppa-Lyonnet
  • Olga M. Sinilnikova
  • Sylvie Mazoyer
  • Laure Barjhoux
  • Melanie Leone
  • Marion Gauthier-Villars
  • Virginie Caux-Moncoutier
  • Antoine de Pauw
  • Agnes Hardouin
  • Pascaline Berthet
  • Helene Dreyfus
  • Sandra Fert Ferrer
  • Marie-Agnes Collonge-Rame
  • Johanna Sokolowska
  • Saundra Buys
  • Mary Daly
  • Alex Miron
  • Mary Beth Terry
  • Wendy Chung
  • Esther M. John
  • Melissa Southey
  • David Goldgar
  • Christian F. Singer
  • Muy-Kheng Maria Tea
  • Daphne Gschwantler-Kaulich
  • Anneliese Fink-Retter
  • Thomas V. O. Hansen
  • Bent Ejlertsen
  • Oskar T. Johannsson
  • Kenneth Offit
  • Kara Sarrel
  • Mia M. Gaudet
  • Joseph Vijai
  • Mark Robson
  • Marion R. Piedmonte
  • Lesley Andrews
  • David Cohn
  • Leslie R. DeMars
  • Paul DiSilvestro
  • Gustavo Rodriguez
  • Amanda Ewart Toland
  • Marco Montagna
  • Simona Agata
  • Evgeny Imyanitov
  • Claudine Isaacs
  • Ramunas Janavicius
  • Conxi Lazaro
  • Ignacio Blanco
  • Susan J. Ramus
  • Lara Sucheston
  • Beth Y. Karlan
  • Jenny Gross
  • Patricia A. Ganz
  • Mary S. Beattie
  • Rita K. Schmutzler
  • Barbara Wappenschmidt
  • Alfons Meindl
  • Norbert Arnold
  • Dieter Niederacher
  • Sabine Preisler-Adams
  • Dorotehea Gadzicki
  • Raymonda Varon-Mateeva
  • Helmut Deissler
  • Andrea Gehrig
  • Christian Sutter
  • Karin Kast
  • Heli Nevanlinna
  • Kristiina Aittomaki
  • Jacques Simard
  • Amanda B. Spurdle
  • Jonathan Beesley
  • Xiaoqing Chen
  • Gail E. Tomlinson
  • Jeffrey Weitzel
  • Judy E. Garber
  • Olufunmilayo I. Olopade
  • Wendy S. Rubinstein
  • Nadine Tung
  • Joanne L. Blum
  • Steven A. Narod
  • Sean Brummel
  • Daniel L. Gillen
  • Noralane Lindor
  • Zachary Fredericksen
  • Vernon S. Pankratz
  • Fergus J. Couch
  • Paolo Radice
  • Paolo Peterlongo
  • Mark H. Greene
  • Jennifer T. Loud
  • Phuong L. Mai
  • Irene L. Andrulis
  • Gord Glendon
  • Hilmi Ozcelik
  • Anne-Marie Gerdes
  • Mads Thomassen
  • Uffe Birk Jensen
  • Anne-Bine Skytte
  • Maria A. Caligo
  • Andrew Lee
  • Georgia Chenevix-Trench
  • Antonis C. Antoniou
  • Susan L. Neuhausen

Summary, in English

Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2 mutation carriers. Methods: IRS1 rs1801123, rs1330645, and rs1801278 were genotyped in samples from 36 centers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analyzed by a retrospective cohort approach modeling the associations with breast and ovarian cancer risks simultaneously. Analyses were stratified by BRCA1 and BRCA2 status and mutation class in BRCA1 carriers. Results: Rs1801278 (Gly972Arg) was associated with ovarian cancer risk for both BRCA1 (HR, 1.43; 95% confidence interval (CI), 1.06-1.92; P = 0.019) and BRCA2 mutation carriers (HR, 2.21; 95% CI, 1.39-3.52, P = 0.0008). For BRCA1 mutation carriers, the breast cancer risk was higher in carriers with class II mutations than class I mutations (class II HR, 1.86; 95% CI, 1.28-2.70; class I HR, 0.86; 95%CI, 0.69-1.09; P-difference, 0.0006). Rs13306465 was associated with ovarian cancer risk in BRCA1 class II mutation carriers (HR, 2.42; P = 0.03). Conclusion: The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers and breast cancer risk in BRCA1 class II mutation carriers. Impact: These findings may prove useful for risk prediction for breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 21(8); 1362-70. (C)2012 AACR.

Avdelning/ar

Publiceringsår

2012

Språk

Engelska

Sidor

1362-1370

Publikation/Tidskrift/Serie

Cancer Epidemiology Biomarkers & Prevention

Volym

21

Issue

8

Dokumenttyp

Artikel i tidskrift

Förlag

American Association for Cancer Research

Ämne

  • Cancer and Oncology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1538-7755